August 26, 2019 | English | عربي
   Add to Twitter
 
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
• New potential gastrointestinal and lung cancer therapies from Boehringer Ingelheim’s innovative oncology pipeline will be combined with the patient-driven drug-development capabilities at MD Anderson

• The Center will initially investigate KRAS pathway inhibitors and a TRAILR2 antibody from Boehringer Ingelheim’s cancer research